Nuvectis Pharma Past Earnings Performance
Past criteria checks 0/6
Nuvectis Pharma's earnings have been declining at an average annual rate of -14.5%, while the Biotechs industry saw earnings growing at 33.8% annually.
Key information
-14.54%
Earnings growth rate
18.30%
EPS growth rate
| Biotechs Industry Growth | 17.04% |
| Revenue growth rate | n/a |
| Return on equity | -191.00% |
| Net Margin | n/a |
| Last Earnings Update | 31 Mar 2026 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Nuvectis Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 26 | 0 | -30 | 10 | 19 |
| 31 Dec 25 | 0 | -29 | 9 | 18 |
| 30 Sep 25 | 0 | -28 | 9 | 18 |
| 30 Jun 25 | 0 | -22 | 8 | 15 |
| 31 Mar 25 | 0 | -20 | 7 | 14 |
| 31 Dec 24 | 0 | -19 | 7 | 13 |
| 30 Sep 24 | 0 | -19 | 8 | 12 |
| 30 Jun 24 | 0 | -21 | 8 | 13 |
| 31 Mar 24 | 0 | -22 | 8 | 15 |
| 31 Dec 23 | 0 | -22 | 8 | 14 |
| 30 Sep 23 | 0 | -22 | 7 | 14 |
| 30 Jun 23 | 0 | -22 | 7 | 14 |
| 31 Mar 23 | 0 | -20 | 7 | 13 |
| 31 Dec 22 | 0 | -19 | 6 | 12 |
| 30 Sep 22 | 0 | -15 | 5 | 3 |
| 30 Jun 22 | 0 | -13 | 4 | 3 |
| 31 Mar 22 | 0 | -16 | 4 | 4 |
| 31 Dec 21 | 0 | -13 | 3 | 2 |
Quality Earnings: NVCT is currently unprofitable.
Growing Profit Margin: NVCT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NVCT is unprofitable, and losses have increased over the past 5 years at a rate of 14.5% per year.
Accelerating Growth: Unable to compare NVCT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NVCT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (43%).
Return on Equity
High ROE: NVCT has a negative Return on Equity (-191%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/20 11:17 |
| End of Day Share Price | 2026/05/20 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Nuvectis Pharma, Inc. is covered by 5 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joseph Pantginis | H.C. Wainwright & Co. |
| I-Eh Jen | Laidlaw & Company (UK) Ltd |
| Christopher Liu | Lucid Capital Markets |